Daniel H Fowler
Overview
Explore the profile of Daniel H Fowler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
5137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhakal B, Hari P, Chhabra S, Szabo A, Lum L, Glass D, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39875173
Background: Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo...
2.
Khan A, Barber D, McKillop W, Rupar C, Auray-Blais C, Fraser G, et al.
Clin Transl Med
. 2025 Jan;
15(1):e70073.
PMID: 39794302
Background: Fabry disease is an X-linked lysosomal storage disorder due to a deficiency of α-galactosidase A (α-gal A) activity. Our goal was to correct the enzyme deficiency in Fabry patients...
3.
Holtzman N, Curtis L, Salit R, Shaffer B, Pirsl F, Ostojic A, et al.
Blood Adv
. 2024 Apr;
8(16):4294-4310.
PMID: 38669315
Chronic graft-versus-host disease (cGVHD) remains a significant problem for patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although in vivo lymphodepletion for cGVHD prophylaxis has been explored in the myeloablative...
4.
Mariotti J, Fowler D, Bramanti S, Pavletic S
Front Immunol
. 2023 May;
14:1212756.
PMID: 37256121
No abstract available.
5.
Saleh A, Rothe M, Barber D, McKillop W, Fraser G, Morel C, et al.
Mol Ther Methods Clin Dev
. 2023 Feb;
28:262-271.
PMID: 36816757
The safety and efficacy of lentivirus-mediated gene therapy was recently demonstrated in five male patients with Fabry disease-a rare X-linked lysosomal storage disorder caused by gene mutations that result in...
6.
Nagree M, Felizardo T, Faber M, Rybova J, Rupar C, Foley S, et al.
EMBO Mol Med
. 2022 Mar;
14(4):e14297.
PMID: 35298086
T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin-conditioning ex vivo reprograms T cells, increasing...
7.
Khan A, Barber D, Huang J, Rupar C, Rip J, Auray-Blais C, et al.
Nat Commun
. 2021 Feb;
12(1):1178.
PMID: 33633114
Enzyme and chaperone therapies are used to treat Fabry disease. Such treatments are expensive and require intrusive biweekly infusions; they are also not particularly efficacious. In this pilot, single-arm study...
8.
Conlon K, Sportes C, Brechbiel M, Fowler D, Gress R, Miljkovic M, et al.
Cancer Biother Radiopharm
. 2020 Apr;
35(4):249-261.
PMID: 32275165
Despite advances in therapy of Hodgkin's lymphoma (HL), a proportion of patients will not respond or relapse. The authors had previously identified CD25, IL-2Rα, as a target for systemic radioimmunotherapy...
9.
Dimitrova D, Gea-Banacloche J, Steinberg S, Sadler J, Hicks S, Carroll E, et al.
Biol Blood Marrow Transplant
. 2019 Sep;
26(1):94-106.
PMID: 31493539
Allogeneic blood or marrow transplantation (BMT) is a potentially curative therapy for patients with primary immunodeficiency (PID). Safe and effective reduced-intensity conditioning (RIC) approaches that are associated with low toxicity,...
10.
Griffith L, VanRaden M, Barrett A, Childs R, Fowler D, Kang E, et al.
Transfusion
. 2018 Oct;
59(1):303-315.
PMID: 30362577
Background: Patients undergoing allogeneic hematopoietic stem cell transplant require variable, often extensive transfusion support. Identification of factors that predict urgent, intensive, or special needs should improve management of these patients....